![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
BAER-101 is a high affinity, selective modulator of the GABA A receptor system, with differential binding and modulatory properties dependent on the particular GABA A subtype.
Lead Product(s): BAER-101
Therapeutic Area: Psychiatry/Psychology Product Name: BAER-101
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Avenue Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 08, 2022